PTI Works with Yale to Further Cancer Treatment
June 7, 2005
Precision Therapeutics has partnered with researchers at the Yale School of Medicine to combine PTI's ChemoFX assay with Yale's apoptosis assay to distinguish drugs that can stop the growth of and/or kill cancer tumors. The test will help physicians predict whether a cancer patient will respond to a specific drug. Recruitment for the clinical study wraps up this month, and results will be available about this same time next year.
« Imago Thinks Small to Go Far | | Congressman Murtha Increases Funding for Diabetes »
